Filgotinib Trial Results for Axial Spondyloarthritis Released
A phase III trial indicates that filgotinib may effectively treat both radiographic and non-radiographic axial spondyloarthritis.
Updated on Oct. 5, 2026 in Arthritis
The phase III OLINGUITO trial has demonstrated the efficacy of filgotinib for patients managing axial spondyloarthritis. The study evaluated outcomes across both radiographic and non-radiographic forms of the condition over a 52-week period.
Why it matters
These results build on previous phase II findings to further clarify the potential role of JAK inhibition in managing axial spondyloarthritis. For patients, this suggests a growing range of options for addressing chronic inflammation linked to this condition.
The OLINGUITO trial included 258 participants with radiographic axial spondyloarthritis and 237 with non-radiographic forms. Researchers evaluated filgotinib over a 16-week double-blind period followed by an open-label phase extending to week 52.
The players
Filgotinib
A JAK1 inhibitor medication researched for the treatment of inflammatory conditions like axial spondyloarthritis.
The details
Filgotinib functions as a JAK1 inhibitor, a class of medication that works by blocking Janus kinase enzymes involved in signaling pathways that drive inflammation. In this trial, participants received a 200 mg daily dose during the double-blind period, with adjustments allowed for those aged 65 and older or with specific risk factors. The study design allowed clinicians to titrate the dose to the lowest effective level during the open-label follow-up to optimize clinical response.
Timeline
16-week double-blind treatment period
Week 52 conclusion of the open-label treatment period
Health Landscape
This trial follows the earlier phase II trial of JAK inhibition for axial spondyloarthritis to validate this treatment class for broader clinical use. It represents a significant step in the ongoing evolution of targeted therapies for chronic inflammatory arthritic conditions.
If you are managing axial spondyloarthritis, these results provide a topic to discuss with your rheumatologist regarding emerging treatment options. Ask your physician how different classes of inhibitors compare to your current regimen and whether new clinical data changes your long-term care plan.
The takeaway
The OLINGUITO trial results suggest that JAK1 inhibition is a viable avenue for managing both radiographic and non-radiographic axial spondyloarthritis. Keep a record of your symptom progression and treatment responses to facilitate an informed conversation with your specialist during your next visit.
Further reading
Learn more about the latest research and standard care approaches in our Arthritis section.
Source note: This article includes information reported by Nature.
